Chicago Atlantic announced its role as sole arranger and administrative agent in the closing of a $16.5 million senior secured term loan for Ocular Science, Inc. (“Ocular Science”), an affiliate of OSRX, Inc. OSRX is a leading provider of compounded ophthalmic medications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115489798/en/
Founded in 2015 and guided by a medical advisory board of 31 world leaders in ophthalmology, Ocular Science focuses on the production of paradigm-shifting therapeutic solutions for eye care that are easy to use, cost-effective and promote patient compliance.
Through its affiliate OSRX, the company focuses on pre-operative, intra-operative and post-operative care for surgical vision correction patients, as well as the management of myopia (nearsightedness) and glaucoma. OSRX, an FDA-registered 503B outsourcing facility, combines practical, physician-informed solutions with innovative approaches designed to improve the patient experience. By compounding multiple medications, OSRX helps physicians streamline their treatment protocols while making affordable medication available to patients.
“Ocular Science is a leading biotech company focused on ophthalmology, guided by a patient-first philosophy and a commitment to manufacturing excellence. The company has built strong relationships with physicians and key opinion leaders nationwide,” said Dino Colonna, Partner at Chicago Atlantic. “Supported by favorable industry tailwinds, including an aging population and a differentiated value proposition that simplifies care delivery, we believe Ocular Science and OSRX are well positioned for continued growth.”
OSRX medications can be delivered directly to patients’ homes or shipped in bulk to medical facilities and can be prescribed to simplify dosing, improve staff efficiency, and deliver straightforward treatment options at cost-effective price points.
“Our company was built by people who believe in doing the right thing for physicians and patients, even in the face of adversity and uncertainty,” said Anthony Sampietro, Founder, President and CEO of Ocular Science and OSRX. “This capital strengthens our foundation, provides critical operating flexibility, and enables us to continue going the extra mile for our customers for many years to come.”
About Chicago Atlantic
Chicago Atlantic is a private market lender focused on industries and companies where demand for capital exceeds traditional supply. The firm focuses on loans to esoteric industries, specialty asset-based loans, liquidity solutions and growth & technology finance. Chicago Atlantic has closed over $3.2 billion in credit facilities since inception. Chicago Atlantic’s team of over 95 professionals has offices in Chicago, Miami, New York and London. For more information visit chicagoatlantic.com.
About Ocular Science
Ocular Science®, headquartered in El Segundo, Calif., is a leading biotech company founded in 2015 by CEO Anthony Sampietro, Chief Medical Officer Damien Goldberg, MD, and Francis Mah, MD. The company focuses on the production, marketing, and sales of compounded ophthalmic products and is guided by a medical advisory board of world leaders in ophthalmology. Learn more at www.ocularscience.com.
About OSRX
OSRX is an FDA-registered 503B outsourcing facility dedicated to advancing ophthalmic care through high-quality compounded solutions that simplify treatment for prescribers and patients. Licensed nationwide, the Montana-based company is trusted by more than 9,500 prescribers and is driven by its mission to deliver A New View of Medicine®. Learn more at www.osrxpharmaceuticals.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260115489798/en/
“Supported by favorable industry tailwinds, including an aging population and a differentiated value proposition that simplifies care delivery, we believe Ocular Science and OSRX are well positioned for continued growth.”
